跳转至内容
Merck
CN

D-047

N-去甲基西酞普兰盐酸盐 盐酸盐 溶液

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

别名:

N-去甲基西酞普兰盐酸盐 盐酸盐 溶液

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C19H19FN2O · HCl
化学文摘社编号:
分子量:
346.83
MDL number:
UNSPSC Code:
41116107
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

N-去甲基西酞普兰盐酸盐 盐酸盐 溶液, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

SMILES string

Fc1ccc(cc1)[C@@]2(OCc3c2ccc(c3)C#N)CCCNC

InChI

1S/C19H19FN2O/c1-22-10-2-9-19(16-4-6-17(20)7-5-16)18-8-3-14(12-21)11-15(18)13-23-19/h3-8,11,22H,2,9-10,13H2,1H3/t19-/m0/s1

InChI key

PTJADDMMFYXMMG-IBGZPJMESA-N

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

concentration

1.0 mg/mL in methanol (as free base)

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

application(s)

clinical testing

format

single component solution

storage temp.

−20°C

Quality Level

General description

N-去甲基西酞普兰是SSRI抗抑郁药西酞普兰的一种活性代谢产物。西酞普兰在美国和加拿大以Celexa®的名义进行销售,可用于治疗与情绪障碍相关的重度抑郁症。

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Celexa is a registered trademark of H. Lundbeck A/S
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes,Central nervous system

存储类别

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

法规信息

危险化学品
此项目有

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Francesca-Maria Raffaelli et al.
Scientific reports, 10(1), 20203-20203 (2020-11-21)
Brown adipose tissue (BAT) thermogenesis is considered a potential target for treatment of obesity and diabetes. In vitro data suggest dopamine receptor signaling as a promising approach; however, the biological relevance of dopamine receptors in the direct activation of BAT
Lili Aslostovar et al.
Cell reports. Medicine, 2(2), 100202-100202 (2021-03-06)
The aberrant expression of dopamine receptors (DRDs) in acute myeloid leukemia (AML) cells has encouraged the repurposing of DRD antagonists such as thioridazine (TDZ) as anti-leukemic agents. Here, we access patient cells from a Phase I dose escalation trial to

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持